- Featured Product
- KD/KO Validated
BCCIP Polyclonal antibody
BCCIP Polyclonal Antibody for IF, IP, WB,ELISA
Host / Isotype
Rabbit / IgG
human, mouse, rat
WB, IP, IHC, IF,ELISA
Cat no : 16043-1-AP
|Positive WB detected in||HeLa cells, A549 cells|
|Positive IP detected in||HeLa cells|
|Positive IF detected in||HeLa cells|
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
|KD/KO||See 2 publications below|
|WB||See 5 publications below|
|IHC||See 1 publications below|
|IF||See 3 publications below|
16043-1-AP targets BCCIP in WB, IP, IHC, IF,ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||BCCIP fusion protein Ag8934|
|Full Name||BRCA2 and CDKN1A interacting protein|
|Calculated molecular weight||314 aa, 36 kDa|
|Observed molecular weight||50-58 kDa|
|GenBank accession number||BC009771|
|Gene ID (NCBI)||56647|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
BCCIP (or TOK1) is isolated as a BRCA2- and CDKN1A (p21)-interacting protein and is implicated in homologous recombination (HR) pathway and inhibition of DNA replication stress. BCCIP is an evolutionarily conserved nuclear protein with multiple interacting domains. BCCIP deficiency in mice impaired embryonic and postnatal neural development, causing severe ataxia, cerebral and cerebellar defects, and microcephaly, which are associated with spontaneous DNA damage and subsequent cell death in the proliferative cell populations of the neural system during embryogenesis. BCCIP is essential for maintaining the transactivation activity of wild type p53 suggesting a potential role of BCCIP in cancer etiology.
|Product Specific Protocols|
|WB protocol for BCCIP antibody 16043-1-AP||Download protocol|
|IF protocol for BCCIP antibody 16043-1-AP||Download protocol|
|IP protocol for BCCIP antibody 16043-1-AP||Download protocol|
|Click here to view our Standard Protocols|
BCCIP binds to and activates its promoter in a YY1-dependent fashion in HCT116 cells.
Human INO80/YY1 chromatin remodeling complex transcriptionally regulates the BRCA2- and CDKN1A-interacting protein (BCCIP) in cells.
Biochem Biophys Res Commun
BCCIPβ facilitates p53 ubiquitination via binding with E6 protein in high-risk HPV positive head and neck squamous cell carcinoma.
Int J Oncol
Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues.
Int J Mol Sci
YY1/BCCIP Coordinately Regulates P53-Responsive Element (p53RE)-Mediated Transactivation of p21Waf1/Cip1.